Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of Zenas BioPharma, Inc. securities related to its September 2024 IPO, alleging misleading statements in the Registration Statement [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Zenas BioPharma overstated its ability to fund operations with existing cash and expected IPO proceeds, leading to materially false public statements [5]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Participation Information - Interested parties can join the class action by visiting the provided link or contacting the law firm directly [3][6]. - A lead plaintiff must file a motion by June 16, 2025, to represent other class members in the litigation [1][3]. Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements and recognition in the field [4].
ZBIO Investors Have Opportunity to Lead Zenas BioPharma, Inc. Lawsuit Filed by The Rosen Law Firm